Lab Automation Market Report: Size, Share and Outlook by 2031

The lab automation market size was valued at US$ 5.76 billion in 2024 and is expected to reach US$ 8.71 billion by 2031; it is estimated to record a CAGR of 6.3% from 2025 to 2031.

The lab automation market is segmented into five major regions-North America, Europe, Asia Pacific (APAC), the Middle East & Africa (MEA), and South & Central America. North America dominated the market in 2024, followed by North America and Europe, respectively.

The lab automation market in South & Central America is divided into Brazil, Argentina, and the Rest of South & Central America. In this region, the public sector remains dominant in healthcare delivery, but the private sector is rapidly catching up, especially in high-density urban centers. Lab automation is adopted to address workforce shortages, reduce diagnostic turnaround times, and standardize lab processes. Major private diagnostic providers-such as Dasa and Grupo Fleury in Brazil, Synlab in Colombia and Chile-are deploying total lab automation platforms that integrate pre-analytical, analytical, and post-analytical processes. Companies such as Roche Diagnostics, Siemens Healthineers, Beckman Coulter, and Abbott have built strong regional distribution and service networks. Roche's cobas modular systems and Beckman Coulter's DxA workflow automation solutions are implemented to meet the high-volume testing needs of centralized labs.

Budget constraints, uneven healthcare access, limited technical expertise, and reliance on imported technologies slow the pace of automation adoption in smaller or rural labs. Government-backed initiatives aimed at strengthening diagnostic capabilities-particularly in areas such as infectious disease management and maternal health-are helping to close critical gaps, and international organizations, including WHO, PAHO, and NGOs, support them. In the long term, South & Central America present a high-potential market for scalable, cost-effective lab automation solutions tailored to diverse healthcare systems and infrastructure levels.

Lab automation market future trend: Integrating AI into fully autonomous diagnostic systems aims to eliminate the last vestiges of manual intervention in clinical workflows. On July 24, 2025, Scopio Labs announced the unveiling of its Complete Blood Morphology (CBM) analyzer-the first-of-its-kind AI-powered solution designed to automate blood morphology analysis fully. Traditionally, one of the most complex and manually intensive processes in diagnostic hematology, blood cell morphology has long resisted automation due to the nuanced interpretation required. With the CBM platform, Scopio Labs introduces a paradigm shift by combining Full-Field Cell Morphology imaging with advanced AI algorithms to deliver autonomous, standardized morphology analysis and reporting at scale. This development aligns with the future of lab automation, where the market is moving beyond mechanization and toward intelligent, decision-capable systems that process samples and interpret complex data. The CBM analyzer reflects a broader trend of automating sophisticated diagnostic processes that previously depended heavily on skilled human expertise. The technology promises to increase efficiency, reproducibility, and diagnostic throughput, while reducing reliance on scarce specialist labor. Such solutions are vital as healthcare systems worldwide grapple with growing patient volumes, workforce shortages, and mounting pressure to deliver faster, more accurate diagnostic insights.

Scopio's achievement underscores the commercial and investment appeal of next-generation lab automation. The company's Series D funding round expansion to US$ 52 million, supported by Viola Growth's US$ 10 million investment, highlights the strong market confidence in platforms that fuse automation, AI, and digital imaging to transform diagnostics. This funding is expected to accelerate the go-to-market strategy for CBM, positioning Scopio at the forefront of AI-enabled laboratory innovation. In the broader context of lab automation trends, the rise of autonomous systems such as Scopio's CBM signals a shift from incremental improvements to full-stack automation, where machines perform technical tasks and cognitive functions. As laboratories evolve into AI-enhanced diagnostic environments, the ability to combine high-resolution imaging, real-time analysis, and standardized reporting within a single automated workflow will become a defining feature of the future lab. The CBM platform represents more than a product innovation; it exemplifies a new era in lab automation, where AI assists scientists and drives the diagnostic process.

Thermo Fisher Scientific Inc.; Siemens AG; Danaher Corp; Honeywell International Inc; Agilent Technologies Inc; Revvity Inc; Analytik Jena GmbH+Co. KG; Abbott Laboratories; Eppendorf SE; and bioMerieux SA are among the key players profiled during this market study. Several other essential market players were also studied and analyzed to get a holistic view of the global lab automation market and its ecosystem.

The overall lab automation market size has been derived using both primary and secondary sources. Exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the lab automation market size. The process also helps obtain an overview and forecast of the market with respect to all the market segments. Also, multiple primary interviews have been conducted with industry participants to validate the data and gain analytical insights. This process includes industry experts such as VPs, business development managers, market intelligence managers, and national sales managers, along with external consultants such as valuation experts, research analysts, and key opinion leaders specializing in the lab automation market.